Cancel

Enhancing Treatment Experiences in Castration-Resistant Prostate Cancer: The Nurse's View

STATEMENT OF NEED Prostate cancer is the most common tumor type affecting men in the United States, with an estimated 174,650 new cases reported each year. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significa...
i3 Health

Clinical Updates and Expert Guidance in Prostate Cancer

STATEMENT OF NEED Prostate cancer is the most common tumor type affecting men in the United States, with an estimated 174,650 new cases reported each year. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significa...
i3 Health

Internal Medicine Comprehensive Review and Update 2020

This CME program from the leading clinical faculty of Harvard Medical School and Massachusetts General Hospital provides comprehensive instruction to ensure clinicians are current with the latest evidence and best practices for: • Cardiovascular Medicine • Pulmonary Medicine • Critical Care • Hematology and Oncology • Mind-Body Medicine • Infectious Diseases • Gastroenterology • Endocrinology • Rheumatology • Nephrology • Travel Medicine • Allergy and Immuno...
Harvard Medical School

Osler Surgery MOC Online Review

The Osler Institute utilized state of the art equipment to record the comprehensive Radiation Oncology Review Course and bring it to you! These audio files are stored “in the cloud” so you can stream them anywhere, anytime, as long as you have an internet connection – your learning experience is almost like being at the live activity, but without travel costs and time away from your practice. The Osler Radiation Oncology Review also offers a variety of live Radiation Oncology board revie...
Osler Institute

Nursing Management of Bone Health in Patients With Cancer

STATEMENT OF NEED Many tumors, such as prostate, breast, lung, and multiple myeloma, affect bone health. Once cancer spreads to the skeletal system, the risk for pain, fractures, hypercalcemia, and nerve compression increases considerably. Several studies have shown that the use of antiresorptive agents such as bisphosphonates and monoclonal antibodies can reduce the morbidity of skeletal complications in patients with cancer and significantly improve quality of life. Combined with preventi...
i3 Health

New Drugs 2018

In 2018, the US Food and Drug Administration (FDA) approved 59 new drugs – the highest number in more than 10 years – including 19 first-in-class agents. Of the 59 new approvals, 73% received priority review. This issue of The Rx Consultant focuses on the new drugs that may be important additions (including a number of “firsts”) in their therapeutic areas: influenza infection, HIV-1 infection, pneumonia and skin infections, nonmetastatic, castration-resistant prostate cancer, endome...
The Rx Consultant

Penn Radiology Oncologic Imaging Essentials (Online Streaming & DVD-ROM)

Penn Radiology responds to the constant challenge of Cancer imaging with Oncologic Imaging Essentials. This activity includes a review of the diagnostic imaging evaluation of common tumors, including breast, head and neck, thoracic and abdominal malignancies. Current state of the art modalities used for oncologic imaging, including CT, MRI, ultrasound, PET-CT and digital mammography will be discussed. Emphasis is placed on the role of imaging in staging, treatment and follow up in order to ...
Meetings By Mail®

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.